Concurrently, a phase 2a trial (NCT04572893) is evaluating the safety and preliminary efficacy of danicamtiv, a selective allosteric activator of cardiac myosin, which may have a role in reversing or preventing LV systolic dysfunction in patients with primary DCM due to myosin heavy chain beta 7 (MYH7) or TTN variants. Here, MYH7 is linked to familial dilated cardiomyopathy.